The direct bilirubin-to-albumin ratio (DBAR) has emerged as a reliable prognostic marker for assessing 28-day mortality in critically ill patients with cirrhosis, as demonstrated by a study utilizing the MIMIC-IV database. Cirrhosis patients in ICUs face high mortality rates, and traditional models like MELD and Child-Pugh have limitations due to complexity and subjective parameters.
The direct bilirubin-to-albumin ratio (DBAR) has emerged as a reliable prognostic marker for assessing 28-day mortality in critically ill patients with cirrhosis, as demonstrated by a study utilizing the MIMIC-IV database. Cirrhosis patients in ICUs face high mortality rates, and traditional models like MELD and Child-Pugh have limitations due to complexity and subjective parameters. DBAR, which combines two key liver function markers—direct bilirubin (reflecting hepatocyte injury) and albumin (indicating liver synthetic ability)—offers a simpler, objective, and accessible alternative.
The study analyzed data from 509 adult cirrhotic patients and found that elevated DBAR values were strongly associated with worse outcomes. Patients with DBAR ≥ 4 were classified as high-risk and demonstrated significantly lower survival rates (56.9% vs. 18.4% mortality within 28 days). Multivariate Cox regression analysis confirmed DBAR as an independent predictor of mortality (HR 1.16), alongside age, lactate, INR, and vasoactive medication use. Kaplan-Meier survival curves and nonlinear restricted cubic spline analysis further validated DBAR’s prognostic accuracy.
DBAR showed good predictive performance (AUC 0.702), comparable to the MELD score (AUC 0.744) and superior to albumin alone (AUC 0.549). Machine learning ranked DBAR among the top predictors of cirrhosis prognosis, alongside lactate and BUN. External validation using the eICU-CRD database confirmed its reproducibility (AUC ≈ 0.71). DBAR’s predictive effect was consistent across subgroups, though variations were noted in patients with ascites and hepatorenal syndrome.
Clinically, elevated DBAR signals severe hepatic dysfunction, inflammation, and malnutrition, making it a practical and cost-effective biomarker for bedside mortality risk assessment in ICU settings.
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
Introduction: Hepatic encephalopathy (HE) is a major cause of hospitalization in patients with advanced liver disease and is associated with significant morbidity, mortality, and healthcare utilization. The management of HE extends beyond ammonia reduction and...
Introduction: Hepatic encephalopathy (HE) is one of the most common and debilitating neuropsychiatric complications of liver disease and portal-systemic shunting. It can present with a broad spectrum of manifestations, ranging from subtle cognitive impairment to...
Introduction: The belief that low or moderate alcohol consumption may confer cardiovascular or overall health benefits has influenced public health messaging for decades. However, emerging evidence has increasingly challenged this concept, particularly as improved analytical...
Introduction: Chronic kidney disease (CKD) is increasingly recognized as a major comorbidity in patients with cirrhosis. The growing global burden of metabolic syndrome, obesity, and diabetes has contributed to a rising prevalence of both liver...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.